Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder

JAMA Neurol. 2017 Aug 1;74(8):1010-1012. doi: 10.1001/jamaneurol.2017.1336.

Authors

Chao Zhang¹, De-Cai Tian¹, Chun-Sheng Yang¹, Bin Han¹, Jing Wang¹, Li Yang¹, Fu-Dong Shi^{1

2}

Affiliations

¹ Tianjin Neurological Institute, Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
² Barrow Neurological Institute, Division of Neurology, St Joseph's Hospital and Medical Center, Phoenix, Arizona.

Abstract

This study examines the safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder.

Publication types

Clinical Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Aquaporin 4 / blood*
Bortezomib / adverse effects
Bortezomib / therapeutic use*
Humans
Longitudinal Studies
Neuromyelitis Optica / blood*
Neuromyelitis Optica / diagnosis
Neuromyelitis Optica / drug therapy*
Recurrence
Treatment Outcome

Substances

Antineoplastic Agents
Aquaporin 4
Bortezomib